国际眼科纵览

• 综述 • 上一篇    下一篇

增生性玻璃体视网膜病变研究进展

董力 魏文斌   

  1. 首都医科大学附属北京同仁医院 北京同仁眼科中心 眼内肿瘤诊治研究北京市重点实验室 眼科学与视觉科学北京市重点实验室,北京 100730
  • 收稿日期:2018-12-29 出版日期:2019-04-25 发布日期:2019-04-30
  • 通讯作者: 魏文斌,Email:weiwenbintr@163.com
  • 基金资助:

    北京市医院管理局“登峰”人才培养计划(DFL20150201);北京市医院管理局临床医学发展专项经费资助(扬帆计划)(ZYLX201307)

Research progress of proliferative vitreoretinopathy

Dong Li, Wei Wenbin   

  1. Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology &Visual Sciences Key Lab., Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
  • Received:2018-12-29 Online:2019-04-25 Published:2019-04-30
  • Contact: Wei Wenbin,Email:weiwenbintr@163.com

摘要:

增生性玻璃体视网膜病变(proliferative vitreoretinopathy,PVR)的基本病理过程是视网膜色素上皮(retinal pigment epithelium,RPE)细胞及神经胶质细胞在玻璃体内的增生和收缩。其发病机制与多种视网膜细胞及细胞因子有关,目前尚未完全阐明。手术干预仍然是当前最主要的治疗手段。手术目的包括修复视网膜裂孔、解除牵拉作用、稳定视网膜结构以及降低复发的风险,但手术不能阻止和预防细胞的增生和发展,故目前倾向于手术联合眼内辅助用药(糖皮质激素、抗代谢性药物等)的方法。但眼内辅助用药治疗PVR的安全性及有效性仍需要进一步证明。(国际眼科纵览,2019, 43: 138-143)

Abstract:

The basic pathological process of proliferative vitreoretinopathy (PVR) is the proliferation and contraction of retinal pigment epithelium (RPE) cells and glial cells in vitreous cavity. Its pathogenesis is related to a variety of retinal cells and cytokines, but it has not yet been fully clarified. Surgical intervention is still the most important treatment at present. The purposes of the operation include repairing retinal holes, relieving traction, stabilizing the structure of the retina and reducing the risk of recurrence. However, surgery cannot prevent the proliferation and development of cells. Therefore, surgery combined with intraocular adjunctive drugs (corticosteroids, antimetabolic drugs, etc.) is recommended at present. However, the safety and efficacy of intraocular adjuvant therapy for PVR still need to be further proved.(Int Rev Ophthalmol, 2019, 43: 138-143)